Scientech Research LLC Makes New Investment in Danaher Corporation $DHR

Key Points

• Scientech Research LLC has acquired a new stake in Danaher Corporation, purchasing 2,873 shares valued at approximately $589,000 as reported in their 13F filing with the SEC.
• Institutional investors currently own 79.05% of Danaher's stock, with significant increases in holdings from firms like Nuveen LLC and GAMMA Investing LLC during the first quarter.
• Danaher reported earnings of $1.80 per share for the recent quarter, exceeding the consensus estimate, and has set a fiscal year 2025 guidance of $7.700-7.800 EPS.

Scientech Research LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,873 shares of the conglomerate's stock, valued at approximately $589,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. Heck Capital Advisors LLC purchased a new position in Danaher during the 4th quarter valued at about $27,000. GHP Investment Advisors Inc. boosted its holdings in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC boosted its holdings in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in Danaher in the first quarter valued at approximately $31,000. Finally, Dunhill Financial LLC boosted its holdings in Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR stock traded up $2.64 during mid-day trading on Thursday, reaching $195.23. The stock had a trading volume of 3,425,999 shares, compared to its average volume of 3,039,142. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a market cap of $139.79 billion, a P/E ratio of 41.54, a price-to-earnings-growth ratio of 2.69 and a beta of 0.75. The business has a 50-day simple moving average of $201.62 and a 200 day simple moving average of $199.15. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter last year, the business posted $1.72 earnings per share. The business's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Insider Buying and Selling

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Deutsche Bank Aktiengesellschaft reduced their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reiterated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Wells Fargo & Company reduced their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.